Disclosure of payments
Securing the future of collaboration between industry and healthcare professionals, healthcare and patients organisations
Collaboration between pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) benefits patients. It is a relationship that has delivered new vaccines and medicines and fosters the innovation that improves patients’ lives. Furthermore, patient organisations (POs) play a critical role in Europe’s healthcare: from prevention and awareness, through research and development, regulatory and HTA decision-making, to service design and outcomes measurement.
Bringing greater transparency to this already well-regulated and vital relationship, builds understanding of industry-POs and HCPs/HCOs collaboration and, in the context of increasing societal expectations on transparency, addresses directly public concerns about interactions between the medical community and the pharmaceutical industry.
As part of their support for further transparency, EFPIA member companies have certified their commitment to the implementation of the disclosure provisions in the EFPIA Code. You can access member companies’ individual certification letters by clicking here.
As part of their support for further transparency, EFPIA member companies have certified their commitment to the implementation of the disclosure provisions in the EFPIA Code. You can access member companies’ individual certification letters by clicking here.
European Disclosure Gateway
As part of its support for greater transparency, the pharmaceutical industry has voluntarily created a single point of access to help any interested stakeholder navigate the publicly available data on details of payments and other benefits in kind made by the industry to HCPs and HCOs across all EFPIA Members countries. Navigate the European Gateway map here.
EFPIA Disclosure
On a voluntary basis, EFPIA has decided to disclose the amounts provided to patients organisations, healthcare professionals and healthcare organisations.
Additional resources to download
-
The EFPIA Disclosure: Where are we for the 7th publication?
In the context of increasing societal expectations on transparency, the disclosure requirements seek to address any public concerns about these interactions by making them open and transparent.23.06.22Read Article -
EFPIA statement in response to The Times article on disclosure
Scientific exchange between industry and the medical community is vital for advancement of patient care. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives.03.04.18Read Article -
Charting our route towards HCP disclosure
Faraz Kermani discusses the need for a greater transparency in the pharmaceutical sector17.03.16Read Article -
New day rising? (Guest blog)
Dominic Tyer talks about how the approaching disclosure of payments to healthcare professionals.25.02.16Read Article -
How does European data privacy legislation impact on the disclosure code?
Julie Bonhomme discusses how the European data privacy legislation impacts the disclosure code19.11.15Read Article -
HCP disclosure is desirable and will improve service to patients (Guest Blog)
Alastair Kent discusses how healthcare professional transparency will improve services to patients11.11.15Read Article -
HCP Disclosure: an Extraordinary Experience from the “Wild East” (Guest Blog)
Jakub Dvořáček discusses how we could learn from the Czeck Republic about disclosing value transfer between health professionals and EFPIA Member Companies28.10.15Read Article -
Sweden’s experience adopting the EFPIA Disclosure Code (Guest Blog)
Rikard Pellas discusses Sweden's experience with adopting the EFPIA Disclosure Code27.10.15Read Article -
EFPIA’s Disclosure Code: The Benefits and Limitations of Transparency (Guest Blog)
Brennan Jacoby discusses the benefits and limitations of transparency within the pharmaceutical industry22.10.15Read Article -
Securing the basis for collaboration
Richard Bergoström discusses how the relationship between industry and healthcare professionals will change with new disclosure policies21.10.15Read Article -
The EFPIA disclosure code
Julie Bonhomme explains what payments will be disclosed at the end of June 2016 with the introduction of the EFPIA Disclosure Code15.10.15Read Article -
Learning the lessons of aggregate disclosure (Guest blog)
Karen Borrer from ABPI discusses the UK perspective on learning the lessons of aggregate disclosure09.10.15Read Article -
Disclosure of payments to HCPs: The Dutch experience (Guest blog)
Paul Wouters from NEFARMA discusses the public disclosure of payments to healthcare professionals in the Netherlands08.10.15Read Article -
Reflections on disclosure at ECC2015
Andrew Powrie-Smith reflects on disclosure at the European Cancer Congress 201530.09.15Read Article -
Moving ahead with transparency
Richard Bergström welcomes EFPIA's disclosure code02.07.13Read Article